Review
BibTex RIS Cite

Parkinson Hastalığı ve Önleyici, Koruyucu ve Rehabilite Edici Sosyal Hizmet

Year 2021, Volume: 2 Issue: 2, 178 - 193, 31.12.2021

Abstract

Parkinson hastalığı henüz modern tıbbın tedavisini bulamadığı süreğen bir hastalıktır. Parkinson hastalığının nedenleri tam olarak bilinmemektedir. İleri yaş, genler ve çevresel etkenlerin etkileşimiyle olduğu düşünülen bir hastalıktır. Yapılan araştırmalarda en önemli bağımsız değişkenin çevresel etmenler olduğu düşünülmekte ve özellikle tarım ilaçlarının yoğun ve yanlış kullanımı suçlanmaktadır. Sosyal hizmet insanların ve toplumların iyilik hallerine katkı veren bir meslektir. Süreğen hastalıklardan birisi ve uzun süreli, pahalı ve zorlu bir hastalık olan Parkinson hastalığı hastaların hayat kalitelerini azalttığı gibi devletlerin de sağlık harcamalarını artırarak sosyal adaletin sağlanmasında önemli bir engel olabilmektedir. Sağlık hakkı ve sağlıklı ve dengeli bir çevrede yaşama hakkına sahip olmak hem üçüncü kuşak insan haklarından birisi hem de Anayasal bir hak olmakla birlikte, çevreyi geliştirmek, çevre sağlığını korumak ve çevre kirlenmesini önlemek de Devletin ve vatandaşların ödevidir. Bu konuda sosyal hizmet mesleğine büyük sorumluluklar düşmektedir. Sosyal hizmet çevre sorunları ve Parkinson hastalığı için önleyici, koruyucu ve rehabilite edici mesleki uygulamalarını tıbbi sosyal hizmet, endüstriyel sosyal hizmet ve insan hakları kapsamında sivil toplum kuruluşları, ilgili kurumlar ve sosyal politika yapıcılarla birlikte disiplinler arası bütüncül çalışmalarla gerçekleştirmelidir.

References

  • Al Sammarraie, H. W. M. (2021). Pestisit fluopyram’ in Parkinson hastalığı ile bağlantısının araştırılması, Yayımlanmamış Doktora Tezi, T.C. Süleyman Demirel Üniversitesi Sağlık Bilimleri Enstitüsü Tıbbi Biyoloji Anabilim Dalı, Isparta.
  • Armstrong, M, J. ve Okun, M, S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA, 323:548-60.
  • Aykaç, Ö. (2011). Parkinson Hastalığında Akatizi. Ankara Üniversitesi, Tıp Fakültesi, Tıpta Uzmanlık Tezi, Ankara.
  • Barker, R. L. (1999). The social work dictionary, NASW Press.
  • Bradley, W.G., Daroff, R.B., Fenichel, G.M. ve Jankovic, J. (2008). Neurology in Clinical Practice, Fifth Edition, 2081-2096.
  • Chaudhuri, K.R. ve Schapira, A.H. (2009). Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol, 8, 464-474.
  • Conway, K.A., Harper J.D. ve Lansbury, P,T. (1998). Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease. Nature Medicine, 4,1318-1320. Cordatto, D.J. (2004). Genetics and Parkinson’s disease. Clin Neurosci, 11, 119- 23.
  • Chen, H., O’Reill, Y., Schwarzschild, M.A. ve Ascherio, A. (2008). Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol, 167(1), 90–5.
  • De Lau, L.M.L., Koudstaal, P.J., Hofman, A. ve Breteler, M.M.B. (2006). Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol, 164(10), 998–1002.
  • Dorsey, E., Constantinescu, R., Thompson, J., Biglan, K., Holloway, R., Kieburtz, K., (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68(5), 384-6.
  • Durmuş, H., Gökalp, M.A. ve Hanagasi, H.A. (2015). Prevalence of Parkinson's disease in Başkale, Turkey: A population based study. Neurol Sci, 36(3), 411-413.
  • Durmuşoğlu, E., Tiryaki, O. ve Canhilal, R. (2010). Türkiye'de pestisit kullanımı, kalıntı ve dayanıklılık sorunları, VII. Türkiye Ziraat Mühendisliği Teknik Kongresi, TMMOB Ziraat Mühendisleri Odası, Ankara, Bildiriler Kitabı 2, 589-607, 11-15 Ocak 2010.
  • Elbaz, A., Bower, J.H. ve Maraganore, D.M. (2002). Risk tables for Parkinsonism and Parkison‟s disease. Journal of Clinical Epidemiology, 55, 25-31.
  • Fahn, S. (2008). The history of dopamine and levodopa in the treatment of Parkinson's disease, MovDisord, 23 Suppl 3, 497-508.
  • Ferris, C.F., Marella, M., Smerkers, B., Barchet, T.M., Gershman, B. ve Matsuno Yagi, A.,. (2013). A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain and behavior, 3(4), 351-66.
  • Gorell, J.M., Johnson, C., Rybicki, B., Peterson, E. ve Richardson, R. (1998). The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology, 50(5), 1346-50.
  • Hansen, F.R., Bendix, T. ve Skov, P. (1993). Intensive, dynamic back-muscle exercises, conventional physiotherapy, or plasebo-control treatment of low-back pain. Spine, 18(1), 98-108.
  • IFSW (2021). Socıal work and the unıted natıons sustaınable development goals, https://www.ifsw.org/social-work-and-the-united-nations-sustainable-development-goals-sdgs/
  • Kab, S., Spinosi, J., Chaperon, L., Dugravot, A., Singh-Manoux, A. ve Moisan, F. (2017). Agricultural activities and the incidence of Parkinson’s disease in the general French population. European journal of epidemiology, 32(3), 203-16.
  • Kalita, J. ve Misra, K. (2018). U. K. Management of advanced parkinson disease: Still a riddle. Neurol India, 66 (6), 1853-1854.
  • Lamberti, P., Armenise, S. ve Castaldo, V. (1997). Freezing gait in Parkinson’s disease. Eur Neurol, 38, 297-301.
  • Le, W., Chen, S. ve Jankovic, J. (2009). Etiopathogenesis of Parkinson Disease: A New Beginning? The Neuroscientist,15(1), 28-35.
  • Levine, C.B., Fahrbach, K.R. ve Siderowf (2003). Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature. Evidence Report/Technology Assessment Number 57. Rockville, MD: Agency for Healthcare Research and Quality. June 2003.
  • Lewis, P.A. (2012). James Parkinson: The man behind the shaking palsy. J Parkinsons Dis, 2(3), 181-187.
  • Mars, U. ve Larsson, B.S. (1999). Pheomelanin as a binding site for drugs and chemicals. Pigment Cell. Res. 12, 266-274.
  • Mostafalou, S. ve Abdollahi, M. (2013). Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives. Toxicology and applied pharmacology, 268(2),157-77. Park, A. ve Stacy, M. (2009). Non-motor symptoms in Parkinson’s disease. J Neurol, 256(3), 293-298.
  • Pilger, A. ve Rudiger, H.W. (2006). 8-Hydroxy-2'-deoxy guanosineas amarker of oxidative DNA damage related to occupation alan environment alexposures,Int Arch occup Environ Health, 80(1), 1–15.
  • Pringsheim, T., Jette, N., Frolkis, A. ve Steeves, T.D. (2014). The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord, 29(13),1583-1590.
  • Raudino, F. (2012). The parkinson disease before james Parkinson, Neurol Sci. 33 (4): 945- 948.
  • Rowland, L.P. (2005). Merritt’s Neurology. Eleventh Edition, 828-845.
  • Selin, Y. B. (2021). Yeşilırmak havzası’nda pestisit kirliliği kaynak belirleme çalışması ve metaller için arka plan konsantrasyonlarının belirlenmesi, Yayımlanmamış Yüksek Lisans, ODTÜ, Çevre Mühendisliği, Ankara.
  • Tanner, C.M. (1992). Epidemiology and genetics of parkinson’s disease. Neurol clin. 10(2), 317–329.
  • Tiryaki, O., Canhilal, R. ve Horuz, S. (2010). Tarım ilaçları kullanımı ve riskleri. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Dergisi 26(2), 154-169.
  • Toğay, V. A. (2021). Pestisit Thiacloprid'in Parkinson hastalığı ile bağlantısının araştırılması, Yayımlanmamış Doktora tezi, Süleyman Demirel Üniversitesi Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji Anabilim Dalı, Isparta.
  • Truong, D. D., Bhidayasiri, R. ve WOLTERS, E. (2008). Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci, 266 (8), 216-228.
  • Twelves, D., Perkins, K.S. ve Counsell, C. (2003). Systematic review of incidence studies of Parkinson's disease. Mov Disord,18(1):19-31.
  • Wan, N. ve Lin, G. (2016). Parkinson's Disease and pesticides exposure: New findings from a comprehensive study in Nebraska, USA. The Journal of Rural Health, 32(3):303-13.
  • Wooten, G.F. (1997). Neurochemistry and neuropharmacology of Parkinson’s disease. In: Watts RL, Koller WC. Eds. Movement Disorders Neurologic principles and practice. McGraw-Hill Companies, 11,1153-1160.

Parkinson's Disease and Preventive, Protective and Rehabilitative Social Work

Year 2021, Volume: 2 Issue: 2, 178 - 193, 31.12.2021

Abstract

Parkinson's disease is a chronic disease for which modern medicine has not yet found a cure. The causes of Parkinson's disease are not fully known. It is a disease that is thought to be caused by the interaction of advanced age, genes and environmental factors. In the researches, it is thought that the most important independent variable is environmental factors, and especially intensive and misuse of pesticides is blamed. Social work is a profession that contributes to the well-being of people and societies. Parkinson's disease, which is one of the chronic diseases and a long-term, expensive and difficult disease, reduces the quality of life of patients and can be an important obstacle in ensuring social justice by increasing the health expenditures of the states. The right to health and the right to live in a healthy and balanced environment is both a third generation human right and a constitutional right. At the same time, it is the duty of the State and citizens to improve the environment, protect environmental health and prevent environmental pollution. In this regard, the social work profession has great responsibilities. Social work should carry out preventive, protective and rehabilitative professional practices for environmental problems and Parkinson's disease through interdisciplinary holistic studies with non-governmental organizations, relevant institutions and social policy makers within the scope of medical social work, industrial social work and human rights.

References

  • Al Sammarraie, H. W. M. (2021). Pestisit fluopyram’ in Parkinson hastalığı ile bağlantısının araştırılması, Yayımlanmamış Doktora Tezi, T.C. Süleyman Demirel Üniversitesi Sağlık Bilimleri Enstitüsü Tıbbi Biyoloji Anabilim Dalı, Isparta.
  • Armstrong, M, J. ve Okun, M, S. (2020). Diagnosis and Treatment of Parkinson Disease. JAMA, 323:548-60.
  • Aykaç, Ö. (2011). Parkinson Hastalığında Akatizi. Ankara Üniversitesi, Tıp Fakültesi, Tıpta Uzmanlık Tezi, Ankara.
  • Barker, R. L. (1999). The social work dictionary, NASW Press.
  • Bradley, W.G., Daroff, R.B., Fenichel, G.M. ve Jankovic, J. (2008). Neurology in Clinical Practice, Fifth Edition, 2081-2096.
  • Chaudhuri, K.R. ve Schapira, A.H. (2009). Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol, 8, 464-474.
  • Conway, K.A., Harper J.D. ve Lansbury, P,T. (1998). Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease. Nature Medicine, 4,1318-1320. Cordatto, D.J. (2004). Genetics and Parkinson’s disease. Clin Neurosci, 11, 119- 23.
  • Chen, H., O’Reill, Y., Schwarzschild, M.A. ve Ascherio, A. (2008). Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol, 167(1), 90–5.
  • De Lau, L.M.L., Koudstaal, P.J., Hofman, A. ve Breteler, M.M.B. (2006). Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol, 164(10), 998–1002.
  • Dorsey, E., Constantinescu, R., Thompson, J., Biglan, K., Holloway, R., Kieburtz, K., (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68(5), 384-6.
  • Durmuş, H., Gökalp, M.A. ve Hanagasi, H.A. (2015). Prevalence of Parkinson's disease in Başkale, Turkey: A population based study. Neurol Sci, 36(3), 411-413.
  • Durmuşoğlu, E., Tiryaki, O. ve Canhilal, R. (2010). Türkiye'de pestisit kullanımı, kalıntı ve dayanıklılık sorunları, VII. Türkiye Ziraat Mühendisliği Teknik Kongresi, TMMOB Ziraat Mühendisleri Odası, Ankara, Bildiriler Kitabı 2, 589-607, 11-15 Ocak 2010.
  • Elbaz, A., Bower, J.H. ve Maraganore, D.M. (2002). Risk tables for Parkinsonism and Parkison‟s disease. Journal of Clinical Epidemiology, 55, 25-31.
  • Fahn, S. (2008). The history of dopamine and levodopa in the treatment of Parkinson's disease, MovDisord, 23 Suppl 3, 497-508.
  • Ferris, C.F., Marella, M., Smerkers, B., Barchet, T.M., Gershman, B. ve Matsuno Yagi, A.,. (2013). A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain and behavior, 3(4), 351-66.
  • Gorell, J.M., Johnson, C., Rybicki, B., Peterson, E. ve Richardson, R. (1998). The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology, 50(5), 1346-50.
  • Hansen, F.R., Bendix, T. ve Skov, P. (1993). Intensive, dynamic back-muscle exercises, conventional physiotherapy, or plasebo-control treatment of low-back pain. Spine, 18(1), 98-108.
  • IFSW (2021). Socıal work and the unıted natıons sustaınable development goals, https://www.ifsw.org/social-work-and-the-united-nations-sustainable-development-goals-sdgs/
  • Kab, S., Spinosi, J., Chaperon, L., Dugravot, A., Singh-Manoux, A. ve Moisan, F. (2017). Agricultural activities and the incidence of Parkinson’s disease in the general French population. European journal of epidemiology, 32(3), 203-16.
  • Kalita, J. ve Misra, K. (2018). U. K. Management of advanced parkinson disease: Still a riddle. Neurol India, 66 (6), 1853-1854.
  • Lamberti, P., Armenise, S. ve Castaldo, V. (1997). Freezing gait in Parkinson’s disease. Eur Neurol, 38, 297-301.
  • Le, W., Chen, S. ve Jankovic, J. (2009). Etiopathogenesis of Parkinson Disease: A New Beginning? The Neuroscientist,15(1), 28-35.
  • Levine, C.B., Fahrbach, K.R. ve Siderowf (2003). Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature. Evidence Report/Technology Assessment Number 57. Rockville, MD: Agency for Healthcare Research and Quality. June 2003.
  • Lewis, P.A. (2012). James Parkinson: The man behind the shaking palsy. J Parkinsons Dis, 2(3), 181-187.
  • Mars, U. ve Larsson, B.S. (1999). Pheomelanin as a binding site for drugs and chemicals. Pigment Cell. Res. 12, 266-274.
  • Mostafalou, S. ve Abdollahi, M. (2013). Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives. Toxicology and applied pharmacology, 268(2),157-77. Park, A. ve Stacy, M. (2009). Non-motor symptoms in Parkinson’s disease. J Neurol, 256(3), 293-298.
  • Pilger, A. ve Rudiger, H.W. (2006). 8-Hydroxy-2'-deoxy guanosineas amarker of oxidative DNA damage related to occupation alan environment alexposures,Int Arch occup Environ Health, 80(1), 1–15.
  • Pringsheim, T., Jette, N., Frolkis, A. ve Steeves, T.D. (2014). The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord, 29(13),1583-1590.
  • Raudino, F. (2012). The parkinson disease before james Parkinson, Neurol Sci. 33 (4): 945- 948.
  • Rowland, L.P. (2005). Merritt’s Neurology. Eleventh Edition, 828-845.
  • Selin, Y. B. (2021). Yeşilırmak havzası’nda pestisit kirliliği kaynak belirleme çalışması ve metaller için arka plan konsantrasyonlarının belirlenmesi, Yayımlanmamış Yüksek Lisans, ODTÜ, Çevre Mühendisliği, Ankara.
  • Tanner, C.M. (1992). Epidemiology and genetics of parkinson’s disease. Neurol clin. 10(2), 317–329.
  • Tiryaki, O., Canhilal, R. ve Horuz, S. (2010). Tarım ilaçları kullanımı ve riskleri. Erciyes Üniversitesi Fen Bilimleri Enstitüsü Dergisi 26(2), 154-169.
  • Toğay, V. A. (2021). Pestisit Thiacloprid'in Parkinson hastalığı ile bağlantısının araştırılması, Yayımlanmamış Doktora tezi, Süleyman Demirel Üniversitesi Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji Anabilim Dalı, Isparta.
  • Truong, D. D., Bhidayasiri, R. ve WOLTERS, E. (2008). Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci, 266 (8), 216-228.
  • Twelves, D., Perkins, K.S. ve Counsell, C. (2003). Systematic review of incidence studies of Parkinson's disease. Mov Disord,18(1):19-31.
  • Wan, N. ve Lin, G. (2016). Parkinson's Disease and pesticides exposure: New findings from a comprehensive study in Nebraska, USA. The Journal of Rural Health, 32(3):303-13.
  • Wooten, G.F. (1997). Neurochemistry and neuropharmacology of Parkinson’s disease. In: Watts RL, Koller WC. Eds. Movement Disorders Neurologic principles and practice. McGraw-Hill Companies, 11,1153-1160.
There are 38 citations in total.

Details

Primary Language Turkish
Subjects Sociology (Other)
Journal Section Reviews
Authors

Bülent Şen This is me 0000-0003-1752-1876

Publication Date December 31, 2021
Published in Issue Year 2021 Volume: 2 Issue: 2

Cite

APA Şen, B. (2021). Parkinson Hastalığı ve Önleyici, Koruyucu ve Rehabilite Edici Sosyal Hizmet. Sosyal Politika Ve Sosyal Hizmet Çalışmaları Dergisi, 2(2), 178-193.